register

News & Trends - Pharmaceuticals

New test enhances checkpoint inhibitor blockade response in melanoma

Health Industry Hub | February 16, 2021 |
[Total: 1    Average: 5/5]

MedTech News: Researchers from QIMR Berghofer Medical Research Institute have developed a prototype test that can help identify if patients with deadly metastasised melanoma are likely to benefit from immunotherapy.

Details about the test and the study are being published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

The prototype test detects levels of the protein LC3B on cancer cells. High levels of LC3B are associated with better patient responses to a form of treatment known as checkpoint inhibitor immunotherapy.

Metastatic melanoma is a very aggressive disease and according to the Australian Institute of Health and Welfare, 1,375 Australians died from it in 2020.

Most patients undergo surgery and almost all patients with metastatic melanoma are now given immunotherapy as a standard frontline treatment.

Lead researcher Associate Professor Jason Lee, who heads QIMR Berghofer’s Epigenetics and Disease group, said immunotherapies have remarkably improved treatment and survival rates for metastatic melanoma, but more than half of all patients do not respond.

“We need to treat these patients quickly and with the correct kinds of drugs to have any success,” Associate Professor Lee said.

“Our study found patients with high levels of LC3B in their tumour cells had significantly longer survival due to better responses to immunotherapy treatment than those with lower levels. The study showed 95% of patients with high LC3B levels were alive after 3 years, compared to 60% of patients with low LC3B levels.”

The researchers used tumour and blood samples collected from melanoma patients before and after treatment to get a better understanding of the role of the LC3B protein in metastatic melanoma and to develop the prototype test.

PhD candidate in QIMR Berghofer’s Epigenetics and Disease group, Greg Kelly, said they also identified that patients with metastatic melanoma had very high levels of the epigenetic enzyme G9a – which acts on LC3B protein.

“The enzyme G9a acts like a traffic jam, reducing the ability of cancer fighting immune cells to reach the tumour,” Mr Kelly said.

“Building on the group’s previous work, we explored how targeting the G9a enzyme could help in the fight against melanoma. Our lab experiments showed inhibiting the G9a enzyme led to higher levels of LC3B proteins so the immune system could re-engage in the fight against melanoma both on its own, and in combination with immunotherapy.”

Associate Professor Lee said the findings provided hope of new treatment options in the future.

“We are now also working to develop a drug that can effectively inhibit the G9a enzyme,” Associate Professor Lee said.

“We believe blocking the activity of G9a enzymes will in turn raise the level of LC3B protein, making patients more responsive to immunotherapy and possibly even other treatments.

“We are actively working to develop a drug that can be used to treat patients, but this will take time.”

Associate Professor Lee said the researchers plan to expand the study using a larger set of patient samples to test the robustness of the prototype test to predict immunotherapy resistance.

The current study was partly funded by the Queensland Emory Development Fund and the Australian Skin and Skin Cancer Centre.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Digital & Innovation

Healthcare Technology Digital Innovations - Shifts in Pharma’s digital health landscape - Deep dive with Dr Ramin Rafiei

Shifts in Pharma’s digital health landscape – Deep dive with Dr Ramin Rafiei

Health Industry Hub | March 1, 2021 |

In this Health Industry Hub interview, Dr Ramin Rafiei takes us on a deep dive into the current digital health […]

More


News & Trends - Pharmaceuticals

Pharma News - Boehringer Ingelheim reduces carbon footprint with launch of reusable inhaler

Boehringer Ingelheim reduces carbon footprint with launch of reusable inhaler

Health Industry Hub | March 1, 2021 |

Pharma News: Boehringer Ingelheim has reinforced its commitment to increased sustainability within the healthcare sector, launching a more eco-friendly version […]

More


Medical

$1.3 billion manufacturing funding opens for medicines and medical devices

Health Industry Hub | March 1, 2021 |

Medical News: The Morrison Government is backing Australia’s medical products manufacturers to grow and create new jobs, with applications for […]

More


News & Trends - Medical Technology

MedTech News - $100 million funding for major advances in medical technology

$100 million funding for major advances in medical technology

Health Industry Hub | March 1, 2021 |

MedTech News: $100 million is being invested into the development of new medical technologies to improve diagnosis and treatment of […]

More